C
andida is the third most common agent responsible for healthcare-associated bloodstream infections and is the most common agent responsible for invasive fungal infections in children (1, 2) . Candidemia is associated with a high mortality and morbidity among hospitalized patients as well as high healthcare costs (3) . Prevalence of candidemia has dramatically increased in the past decade (4, 5) . Candida species is implicated in 8%-10% of bloodstream infections in PICUs in various studies (6) (7) (8) . In recent years, we have also witnessed and alarming rise in the prevalence of Candida colonization and candidemia. Colonization by Candida species was seen in 69.2% of patients receiving broad spectrum antibiotics for sepsis or septic shock in our PICU (9) , and candidemia was seen in 4.3% of patients (10) .
Objective: To evaluate the efficacy of probiotics in prevention of Candida colonization in a PICU. Design: Prospective double blinded, randomized controlled trial. Setting: PICU of a tertiary care teaching hospital in north India. Subjects: One hundred fifty children (106 boys, 44 girls), 3 months to 12 yrs old, on broad spectrum antibiotics for at least 48 hrs were randomized using computer-generated random numbers to receive probiotic mix (EUGI) (n = 75) or placebo (n = 75). Intervention: Patients received one sachet twice a day of either probiotics or placebo for 7 days. Probiotics contained Lactobacillus acidophillus, Lactobacillus rhamnosum, Bifidobacterium longum, Bifidobacterium bifidum, Saccharomyces boulardi, Saccharomyces thermophilus, fructo-oligosaccharides; and placebocontained lactose packed in similar-looking sachets. Rectal swabs for fungal culture were taken at day 0, 7, and 14 of enrollment. Primary outcome measure was prevalence of rectal colonization with Candida on day 14 postenrollment; secondary outcomes were growth of Candida in urine (candiduria) and blood (candidemia). Patients were followed until completion of 14 days study period or death of patient. Results: Demographic and clinical variables were comparable in two groups. Prevalence of Candida colonization on day 0 was similar (15 of 75) in both the groups. On day 7, 27.9% (19 of 68) patients in the probiotic group and 42.6% (29 of 68) patients in the placebo group were colonized (relative risk 0.65; 95% confidence interval 0.41-1.05; p = 0.07), whereas, on day 14, colonization was observed in 31.3% (21 of 67) patients in the probiotic group and 50% (34 of 68) in the placebo group (relative risk 0.63; 95% confidence interval 0.41-0.96; p = 0.02). Thus, the relative reduction in prevalence of Candida colonization on day 7 and 14 in the probiotic group was 34.5% and 37.2%, respectively. The increase in number of colonized patients from day 0 to 7 and day 0 to 14 was significant in the placebo group (p = 0.004 and 0.001, respectively) but not in the probiotic group (p = 0.30 and 0.19, respectively; McNemar test). Candiduria was significantly less common in the probiotic group than in the placebo group (17.3% vs. 37.3%; relative risk 0.46; 95% confidence interval 0.26-0.82; p = 0.006). However, prevalence of candidemia did not differ significantly in two groups (1.6% in the probiotic group vs. 6.35% in placebo group; relative risk 0.46; 95% confidence interval 0.08-2.74; p = 0.39). Conclusions: Supplementation with probiotics could be a potential strategy to reduce gastrointestinal Candida colonization and candiduria in critically ill children receiving broad spectrum antibiotics. ( Several factors are known to predispose critically ill children to Candida colonization and candidemia. These include broad spectrum antibiotic therapy, use of invasive cannula, invasive hemodynamic monitoring, indwelling urinary catheter, endotracheal intubation, mechanical ventilation, presence of multiple organ failure, use of antacids and H 2 blockers, and malnutrition (10, 11) . Candida colonization is most frequently reported to be associated with an increased risk of development of candidemia in critically ill patients in medical, surgical, and neonatal ICUs (9, (12) (13) (14) . The gastrointestinal tract (GIT) has been implicated as the major site of colonization (15, 16) .
Normal intestinal microbiota is composed of a complex collection and balance of microorganisms that normally inhabit the healthy gastrointestinal tract (17) . Endogenous flora, gastric acidity, peristalsis, and secretion of antibacterial substances are important for maintenance of microbial balance in the GIT. These local defense mechanisms (colonization resistance) may be altered in critically ill patients, thus facilitating Candida colonization and overgrowth (18) .
Achieving a reduction in rates of fungal colonization by using systemic antifungal drugs has been proven to be effective in preventing invasive fungal infection in the pediatric setting (19) (20) (21) . However, prophylaxis with antifungal agents raises concern about their tolerability, cost, and potential selection of resistant strains, and it is not yet implemented as a standard of care (22) (23) (24) . Reinforcement of the intestinal mucosal barrier with administration of commensal bacteria (probiotics) as drug or food supplements can act as an effective tool for prevention of nosocomial fungal infections. Probiotics modify the enteric microflora by colonizing GIT and reduce overgrowth of pathogens, hence colonization and invasive infection (25) . Few trials have reported beneficial effect of probiotics in the prevention of the enteric colonization by Candida in preterm newborns (26, 27) , but no such trial exists in critically ill pediatric patients. The objectives of this study were 1) to evaluate the hypothesis that supplementation with probiotics may reduce the Candida colonization in critically ill children on broad spectrum antibiotics and 2) to determine the effect of probiotics on prevalence of candiduria and candidemia in these patients.
MaterIalS anD MethODS
This was a double blind randomized controlled trial conducted in the PICU of a tertiary care teaching hospital in north India during a 1-yr period from November 2007 to October 2008. The ethics committee of the institute approved the study. Informed written consent was obtained from the parents.
Children (3 months to 12 yrs) admitted to the PICU who had received broad spectrum antibiotics for a minimum of 48 hrs were eligible for inclusion. Children with known chronic illness, immunodeficiency states, and on prior antifungal therapy and probiotics were excluded from the study.
The sample size was calculated on the basis of outcome on day 14 with the assumption that pretrial prevalence of gastrointestinal Candida colonization in children in our PICU after receiving 2 wks of broad spectrum antibiotic therapy was 43% (9) , and use of probiotics will reduce it to 25%. Considering a 5% level of significance, 80% power, and 10% dropout, the minimum sample size was calculated as 72 children in each of the two groups.
All patients satisfying inclusion criteria were enrolled consecutively and randomized by using a computer-generated randomization , and lactose as base) or placebo, which contained only lactose. Both probiotics and placebo were packed in similar-looking sachets, and these sachets were placed in similar-looking envelopes, each containing 14 sachets. All patients received one sachet twice a day for 7 days. Neither the treating physician nor the patients/parents were aware of the nature of the drug used. A person not involved with patient assignment, data collection, and analysis prepared the packets. Randomization codes were broken after the initial analysis was done.
Rectal swabs for fungal cultures were taken on day 0, 7, and 14 of enrollment. Urine was submitted for fungal culture twice a week, and blood culture was sent for fungal cultures if clinically indicated as per unit's protocol (10) . Rectal swabs were immediately transported to a Mycology laboratory at room temperature. Each swab was transferred into two culture tubes containing Sabouraud agar media with antibiotics (Chloramphenicol 50 mg/L and Gentamicin 20 mg/L of media). The culture tubes were then incubated at 22°C and 37°C separately for 7 days. Candida growth was identified by morphological and biochemical tests such as a germ tube test, urease test, sporulation on corn meal agar, sugar fermentation test, and sugar assimilation test. Colonization was defined as positive culture for Candida species from the surveillance site (i.e., rectum). Candidemia was defined as isolation of Candida species in blood culture. Candiduria was defined as isolation of Candida species from urine.
Antifungal drugs were used as per our PICU protocol. Children who had grown Candida in blood culture (candidemia) and who had features of severe sepsis despite being on broad spectrum antibiotics for 5-7 days were given empirical antifungal therapy. These children were started on intravenous Amphotericin-B. Clinically stable patients with candiduria were treated with Fluconazole. Ten patients in the probiotic group and 15 patients in the placebo group received antifungal drugs (p = 0.27; Table 1 ). These patients remained enrolled in the study until the end point, and were not excluded.
Outcome
Primary outcome measure was prevalence of Candida colonization (isolation of Candida from rectal swab) on day 14 postenrollment. Secondary outcomes were growth of Candida in urine (candiduria) or blood (candidemia). Patients were followed until completion of the 14-day study period or death.
Data analysis
Appropriate data entry and statistical analysis were performed on Microsoft Excel 2007 (Microsoft, Redmond, WA) and SPSS 
reSUltS
The study flow chart, recruitment, and randomization are depicted in Figure 1 . Of 150 patients' enrolled in the study, 75 were randomized into group A and group B. Two groups were similar with respect to demographic and clinical characteristics, known risk factors for fungal colonization and invasive fungal infection, and antibiotics and antifungals usage (Table 1) .
Candida Colonization
Prevalence of Candida species colonization on day of enrollment (day 0) was similar in both the groups; 15 patients (20%) were colonized in each group. Seven patients died in each group between day 0 and 7, and one patient died in probiotic group between days 7-14. Table 2 ). Thus, the relative reduction in prevalence of Candida colonization in probiotics users was 34.5% and 37.2% on day 7 and day 14, respectively. The change in number of colonized patients in the two groups on day 7 and day 14 with respect to initial colonization status (on day 0) is shown in Table 3 and Figure 2 . In the placebo group, there was a significant increase in Candida colonization from day 0 to 7 and day 0 to 14 (p = 0.004 and 0.001, respectively), but the change was not significant in the probiotic group (p = 0.30 and 0.19, respectively). The total number of patients colonized at any time during the study period were significantly lower in the probiotic group than in the placebo group (32 vs. 45; p = 0.03; Fig. 2 ). The total number of rectal swabs taken in the probiotic group were 210, out of which 55 (26.2%) were positive for Candida. In contrast, in the placebo group, 78 (37%) of 211 rectal swabs showed growth of Candida (relative risk 0.71; 95% CI 0.53-0.94; p = 0.01; Fig. 2 and Table 2 ).
Candiduria
Candiduria was found in a significantly lower number of patients in the probiotic group (17.3%, 13 of 75) as compared to the placebo group (37.3%, 28 of 75) (relative risk 0.46; 95% CI 0.26-0.82; p = 0.006; Table 2 ).
Candidemia
Blood for fungal culture was obtained from 62 patients in the probiotic group and 63 patients in the placebo group. Candidemia (due to Candida albicans) was found in one patient (1.6%) in the probiotic group as compared to four patients (6.3%) (C. albicans in two and Candida tropicalis and Pichia anomala from one patient each) in the placebo group (relative risk 0.25; 95% CI 0.03-2.21; p = 0.36).
The predominant colonizing species in GIT was C. albicans followed by C. tropicalis. Similarly, C. albicans was also the most common species responsible for candiduria followed by C. tropicalis. The distribution of individual species causing colonization and candiduria was similar in the two groups ( Table 4) . There was no difference in final outcome in the two groups (p = 0.78).
DISCUSSIOn
The present study demonstrates that the concurrent administration of probiotics for 1 wk in critically ill children receiving broad spectrum antibiotic therapy decreased the prevalence of Candida colonization by 34.5% on day 7 and 37.2% on day 14. These results are similar to the ones obtained on preterm neonates (26, 27) and suggest that supplementation of probiotics could be a potentially effective strategy in reducing Candida Flow chart showing colonization of patients with Candida species during study period from day 0 to 14. C = colonization; S = sterile. ªOne patient died in probiotic group between day 7 and 14; b out of 11 newly colonized patients from day 7 to 14 in probiotic group, four were already colonized on day 0. Total patients colonized in probiotic group during the study period were 32. Total swabs positive for Candida were 55; c out of 11 newly colonized patients from day 7 to 14 in placebo group, one patient was already colonized on day 0. Total patients colonized in placebo group during study period were 45. Total swabs positive for Candida were 78. colonization in critically ill children in the PICU receiving broad spectrum antibiotics.
The use of broad-spectrum antibiotics alters the intestinal milieu, favoring colonization and infections with pathogenic bacteria and fungi (28) , which is a known risk factor for invasive candidiasis (12) . In a previous study, we had reported that the prevalence of Candida colonization and candidemia in children admitted in the PICU for treatment of severe sepsis and septic shock was 69.2% (45 of 65) and 30.7% (20 of 65), respectively; 90% of patients (18 of 20) who developed candidemia were colonized with Candida (9). Tortorano et al (29) also found that mucous membrane colonization preceded fungemia in 83% of patients.
A reduction in Candida colonization has been suggested as a strategy to reduce prevalence of invasive candidiasis. Preventive use of systemic antifungal agents has shown promising results (22, 23) . Wainer et al (21) described a two-fold reduction in gut colonization by fungi with the use of a miconazole oral gel in high-risk preterm neonates. Using prophylactic intravenous fluconazole, a three-fold reduction in rectal colonization was achieved in preterm neonates (19) . However, the prophylactic use of antifungal drugs is associated with selection of resistant strains, increased cost, and adverse effects (22) . Therefore, there is a need to test other safer strategies to reduce Candida colonization.
During the past decade, several in vitro and in vivo studies have explored the possible role of probiotics in prevention of Candida colonization and invasive candidiasis. Wagner et al (30) demonstrated that oral and anal inoculation of probiotics (L. acidophilus, Lactobacillus reuteri, Lactobacillus casei GG, and Bifidobacterium animalis) in immunodeficient mice reduced the density of C. albicans in GIT, prevalence of systemic candidiasis, and prolonged the survival of adult and neonatal mice. Zwolinska-Wcislo et al (31) found that L. acidophilus therapy shortened the duration of fungal colonization of gastrointestinal mucosa and attenuated the effect of fungal colonization on process of ulcer healing in patients with gastric ulcer and ulcerative colitis. Manzoni et al (27) showed that orally administered L. casei subspecies rhamnosus significantly reduced the prevalence (23.1% in probiotic group and 48.8% in placebo group) and the intensity of enteric colonization by Candida species among very low birth weight neonates. Romeo et al (26) also found that the use of probiotics seems to be effective in the prevention of gastrointestinal colonization by Candida apart from reducing the prevalence of late-onset sepsis.
Normally intestinal bacterial flora inhibits Candida growth by competing for both adhesion sites and nutrients (32) . Probiotics modify gut ecology and prevent fungal colonization by directly competing with pathogenic microorganisms and indirectly by enhancing the function of the intestinal barrier and the modification of the immune response (33) . Probiotics activate mucosal immunity and stimulate cytokine production, immunoglobulin A secretion, and phagocytosis (33, 34) . In vitro studies have clearly shown inhibitory effect of probiotics individually and as mix on germination of Candida (conversion of yeast to germ). Tang et al (35) A significant finding of our study was almost 50% reduction in prevalence of candiduria in the probiotic group as compared with the placebo group. Candiduria is considered as a marker of heavy colonization (36) and a useful indicator of systemic candidiasis (37) particularly in critically ill children (38) . A reduction in candiduria with the use of probiotics therefore is a good indicator that probiotics may offer a protection against invasive candidiasis.
The major strengths of our study are that this was a double blind, randomized controlled trial with an adequate sample size for the primary outcome. Also all patients completed the study. The results of the study can be generalized to pediatric patients receiving broad spectrum antibiotics in a PICU similar to ours. A confirmation of our findings and evaluation of the effectiveness of probiotics to reduce invasive candidiasis is a multicentric study covering different geographical location is needed. In the present study, there was a trend toward lower rate of candidemia in the probiotic group compared to the placebo group, though the difference was not statistically significant as the sample size was not adequate to study this outcome.
We conclude that probiotics were effective in reducing Candida colonization in GIT and candiduria in critically ill children receiving broad spectrum antibiotic therapy. Concurrent use of probiotics with antibiotics should be evaluated as a strategy to reduce the Candida colonization and prevalence of candidemia in critically ill children, in a multicentric study.
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